|Articles|June 8, 2017
Exom Group starts Caravaggio Study, Cloud & Mobile Clinical Trial
Advertisement
Exom Group launched the Caravaggio Study, a Cloud & Mobile Clinical Trial, that will randomize around 1, 200 patients from 160 clinical sites spanning Europe, Israel, and the U.S.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
How the NIMBLE Study Supported Adherence With Quarterly Dosing of CemdisiranSeptember 18th 2025
Everything to Know About FDA’s Push Towards Radical Transparency in 2025September 17th 2025
IQVIA and Veeva Join Forces to Improve Efficiency and Patient OutcomesSeptember 17th 2025
Managing Background Therapies in the NIMBLE Phase III TrialSeptember 17th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
2
Why Clinical Trials Are at a Crossroads and How Site Networks Are the Key to Success
3
Everything to Know About FDA’s Push Towards Radical Transparency in 2025
4
Phase IV Trial Shows Strong Immune Response from Moderna’s Updated Spikevax Against LP.8.1 Variant of COVID-19
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
